Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration

Cell Death and Differentiation

Volumn 22, Issue 8, 2015, Pages 1275-1286

  Buchheit, C L ^a   Angarola, B L ^a   Steiner, A ^a   Weigel, K J ^a   Schafer, Z T ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; BIM PROTEIN; CASPASE 3; CASPASE 7; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; SHORT HAIRPIN RNA; APOPTOSIS REGULATORY PROTEIN; BCL2L11 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN;

ANOIKIS; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL SURVIVAL; CELL VIABILITY ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATORY BREAST CANCER; LENTIVIRINAE; LYMPH VESSEL; MCF 10A CELL LINE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CELL LINE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANOIKIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-LIKE PROTEIN 11; CELL LINE; CELL SURVIVAL; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST NEOPLASMS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS;

EID: 84935683203     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.209     Document Type: Article

References (48)

1. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH et al. Trends for inflammatory breast cancer: is survival improving? Oncologist 2007; 12: 904-912.
2. Woodward WA, Cristofanilli M. Inflammatory breast cancer. Semin Radiat Oncol 2009; 19: 256-265.
3. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003; 55: 1200-1208.
4. Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res 2005; 7: 52-58.
5. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist 2012; 17: 891-899.
6. Crane K. Elucidating an uncommon disease: inflammatory breast cancer. J Natl Cancer Inst 2011; 103: 1358-1360.
7. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010; 60: 351-375.
8. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000; 2: 423-429.
9. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13: 869-878.
10. Ditsch N, Vodermaier A, Hinke A, Burghardt S, Lenhard M, Lohrs B et al. Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer. Anticancer Res 2012; 32: 3539-3545.
11. Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van Golen KL. Regulation of inflammatory breast cancer cell invasion through Akt1/PKBalpha phosphorylation of RhoC GTPase. Mol Cancer Res 2012; 10: 1306-1318.
12. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004; 6: R110-R115.
13. van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 2002; 1: 575-583.
14. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H et al. A novel putative lowaffinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5: 2511-2519.
15. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60: 5832-5838.
16. Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L et al. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res 2013; 73: 6516-6525.
17. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-562.
18. Buchheit CL, Rayavarapu RR, Schafer ZT. The regulation of cancer cell death and metabolism by extracellular matrix attachment. Semin Cell Dev Biol 2012; 23: 402-411.
19. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008; 272: 177-185.
20. Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer 2014; 14: 632-641.
21. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012; 136: 331-345.
22. Haenssen KK, Caldwell SA, Shahriari KS, Jackson SR, Whelan KA, Klein-Szanto AJ et al. ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J Cell Sci 2010; 123(Pt 8): 1373-1382.
23. Reginato MJ, Mills KR, Becker EB, Lynch DK, Bonni A, Muthuswamy SK et al. Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol 2005; 25: 4591-4601.
24. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009; 461: 109-113.
25. Whelan KA, Schwab LP, Karakashev SV, Franchetti L, Johannes GJ, Seagroves TN et al. The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance. J Biol Chem 2013; 288: 15865-15877.
26. He X, Ota T, Liu P, Su C, Chien J, Shridhar V. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010; 70: 3109-3118.
27. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003; 5: 733-740.
28. Grassian AR, Schafer ZT, Brugge JS. ErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cells. J Biol Chem 2011; 286: 79-90.
29. Parton M, Dowsett M, Ashley S, Hills M, Lowe F, Smith IE. High incidence of HER-2 positivity in inflammatory breast cancer. Breast 2004; 13: 97-103.
30. Hartman ZC, Yang XY, Glass O, Lei G, Osada T, Dave SS et al. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res 2011; 71: 4380-4391.
31. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P et al. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 2009; 15: 6639-6648.
32. Weigel KJ, Jakimenko A, Conti BA, Chapman SE, Kaliney WJ, Leevy WM et al. CAFsecreted IGFBPs regulate breast cancer cell anoikis. Mol Cancer Res 2014; 12: 855-866.
33. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011; 1: 352-365.
34. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 2004; 101: 15313-15317.
35. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 2005; 12: 1008-1014.
36. O'Reilly LA, Kruse EA, Puthalakath H, Kelly PN, Kaufmann T, Huang DC et al. MEK/ERKmediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation. J Immunol 2009; 183: 261-269.
37. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287-296.
38. Luo S, Garcia-Arencibia M, Zhao R, Puri C, Toh PP, Sadiq O et al. Bim inhibits autophagy by recruiting Beclin 1 to microtubules. Mol Cell 2012; 47: 359-370.
39. Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, Dewhirst MW, Devi GR. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 2012; 132: 109-119.
40. Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T et al. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther 2008; 7: 38-47.
41. Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 2013; 32: 3420-3431.
42. Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008; 27 (Suppl 1): S149-S157.
43. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012; 149: 780-794.
44. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785-6793.
45. Fukazawa H, Noguchi K, Masumi A, Murakami Y, Uehara Y. BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitors. Mol Cancer Ther 2004; 3: 1281-1288.
46. Avivar-Valderas A, Salas E, Bobrovnikova-Marjon E, Diehl JA, Nagi C, Debnath J et al. PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment. Mol Cell Biol 2011; 31: 3616-3629.
47. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008; 19: 797-806.
48. Davison CA, Durbin SM, Thau MR, Zellmer VR, Chapman SE, Diener J et al. Antioxidant enzymes mediate survival of breast cancer cells deprived of extracellular matrix. Cancer Res 2013; 73: 3704-3715.